1. Medtech Insight
  2. >>Business

Fractyl Adds $100M Investment To Address Root Causes Of Type 2 Diabetes

 
• By Reed Miller

The series F financing will allow the company to expand clinical research supporting its unique duodenal mucosal resurfacing approach to treating metabolic disease at its source.

Fractyl Health's Revita DMR
Fractyl Health's Revita duodenal mucosal resurfacing (DMR) catheter • Source: Fractyl Health

Fractyl Health, formerly called Fractyl Laboratories, closed a $100m Series F financing to support the ongoing development of duodenal mucosal resurfacing (DMR) technology that addresses the root causes of type 2 diabetes, the Massachusetts company announced on 16 June.

“The [ongoing] emergence from the pandemic has created an opportunity for us to begin to accelerate our plans for advancing our clinical programs,” Fractyl CEO Harith Rajagopalan told Medtech Insight....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By Shubham Singh

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.